Raymond James assumed coverage of Scholar Rock (SRRK) with a Strong Buy rating with a price target of $53, up from $49. Scholar Rock’s apitegromab, a mAb targeting latent myostatin, is progressing towards a September 22 PDUFA date in spinal muscular atrophy, and while expectations are elevated in front of approval, apitegromab has the makings of a commercial winner, the analyst tells investors in a research note. Beyond SMA, Scholar Rock’s myostatin programs have high value expansion opportunities in other neuromuscular indications, while potential outlicensing and partnerships in the obesity space can offer another source of near-term optionality, Raymond James argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock initiated with an Overweight at Cantor Fitzgerald
- JPMorgan adds Scholar Rock to Focus List, ‘Positive Catalyst Watch’
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
- Buy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results
- Strategic Focus on Neuromuscular Treatments and Promising Study Results Justify Buy Rating for Scholar Rock